PEP-CMV

About Helocyte

Helocyte is a clinical-stage biotech advancing a pipeline of immunotherapies for cytomegalovirus (CMV) and other infectious diseases. The company's lead candidate, Triplex, is a modified vaccinia Ankara (MVA) vector-based vaccine designed to prevent CMV reactivation in transplant recipients, having progressed into Phase 2 clinical trials. Helocyte operates as a private entity, leveraging strategic partnerships and investor backing to advance its programs in a significant unmet medical market. Its focus on high-risk patient populations, such as hematopoietic stem cell and solid organ transplant patients, positions it in a specialized but critical niche.

Therapeutic Areas